Experimental human infection with norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity

Clinical and Vaccine Immunology

Volumn 22, Issue 2, 2015, Pages 221-228

  Czakó, Rita ^a   Atmar, Robert L ^a   Opekun, Antone R ^a   Gilger, Mark A ^a   Graham, David Y ^a   Estes, Mary K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; NORMAL HUMAN; NOROVIRUS; NOROVIRUS INFECTION; PHYLOGENY; SEROLOGY; VIRAL GASTROENTERITIS; VIRUS ATTACHMENT; VIRUS IMMUNITY; VIRUS LIKE AGENT; ADULT; BLOOD; CALICIVIRUS INFECTION; CLASSIFICATION; COHORT ANALYSIS; CROSS REACTION; GENETICS; IMMUNOLOGY; NORWALK VIRUS; VIROLOGY;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; COHORT STUDIES; CROSS REACTIONS; GENOTYPE; HUMANS; NORWALK VIRUS;

EID: 84921993924     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00516-14     Document Type: Article

References (49)

1. Hall AJ. 2012. Noroviruses: the perfect human pathogens? J Infect Dis 205:1622-1624. Http://dx.doi.org/10.1093/infdis/jis251.
2. Ramani S, Atmar RL, Estes MK. 2014. Epidemiology of human noroviruses and updates on vaccine development. Curr Opin Gastroenterol 30: 25-33. Http://dx.doi.org/10.1097/MOG.0000000000000022.
3. Kroneman A, Vega E, Vennema H, Vinjé J, White PA, Hansman G, Green K, Martella V, Katayama K, Koopmans M. 2013. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 158:2059-2068. Http://dx.doi.org/10.1007/s00705-013-1708-5.
4. Van Beek J, Ambert-Balay K, Botteldoorn N, Eden JS, Fonager J, Hewitt J, Iritani N, Kroneman A, Vennema H, Vinjé J, White PA, Koopmans M. 2013. Indications for worldwide increased norovirus activity associated with emergence of a new variant of genotype II.4, late 2012. Euro Surveill 18:8-9. Http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId-20345.
5. Giammanco GM, De Grazia S, Terio V, Lanave G, Catella C, Bonura F, Saporito L, Medici MC, Tummolo F, Calderaro A, Bányai K, Hansman G, Martella V. 2014. Analysis of early strains of the norovirus pandemic variant GII.4 Sydney 2012 identifies mutations in adaptive sites of the capsid protein. Virology 450-451:355-358. Http://dx.doi.org/10.1016/j.virol.2013.12.007.
6. Eden J-S, Hewitt J, Lim KL, Boni MF, Merif J, Greening G, Ratcliff RM, Holmes EC, Tanaka MM, Rawlinson WD, White PA. 2014. The emergence and evolution of the novel epidemic norovirus GII.4 variant Sydney 2012. Virology 450-451:106-113. Http://dx.doi.org/10.1016/j.virol.2013.12.005.
7. Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. 2012. The potential economic value of a human norovirus vaccine for the United States. Vaccine 30:7097-7104. Http://dx.doi.org/10.1016/j.vaccine.2012.09.040.
8. Parker SP, Cubitt WD, Jiang XJ, Estes MK. 1994. Seroprevalence studies using a recombinant Norwalk virus protein enzyme immunoassay. J Med Virol 42:146-150. Http://dx.doi.org/10.1002/jmv.1890420209.
9. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. 1990. Multiple- challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis 161:18-21. Http://dx.doi.org/10.1093/infdis/161.1.18.
10. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. 1977. Clinical immunity in acute gastroenteritis caused by Norwalk agent.NEngl J Med 297:86-89. Http://dx.doi.org/10.1056/NEJM197707142970204.
11. Cannon JL, Lindesmith LC, Donaldson EF, Saxe L, Baric RS, Vinjé J. 2009. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol 83:5363-5374. Http://dx.doi.org/10.1128/JVI.02518-08.
12. Lindesmith LC, Beltramello M, Donaldson EF, Corti D, Swanstrom J, Debbink K, Lanzavecchia A, Baric RS. 2012. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 8:e1002705. Http://dx.doi.org/10.1371/journal.ppat.1002705.
13. Siebenga JJ, Vennema H, Renckens B, de Bruin E, van der Veer B, Siezen RJ, Koopmans M. 2007. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol 81:9932-9941. Http://dx.doi.org /10.1128/JVI.00674-07.
14. Simmons K, Gambhir M, Leon J, Lopman B. 2013. Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis 19:1260-1267. Http: //dx.doi.org/10.3201/eid1908.130472.
15. Lindesmith LC, Donaldson E, Leon J, Moe CL, Frelinger JA, Johnston RE, Weber DJ, Baric RS. 2010. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol 84:1800-1815. Http://dx.doi.org/10.1128/JVI.02179-09.
16. Swanstrom J, Lindesmith LC, Donaldson EF, Yount B, Baric RS. 2013. Characterization of blockade antibody responses in GII.2.1976 SMVinfected subjects. J Virol 88:829-837. Http://dx.doi.org/10.1128/JVI.02793-13.
17. Wyatt RG, Dolin R, Blacklow NR, DuPont HL, Buscho RF, Thornhill TS, Kapikian AZ, Chanock RM. 1974. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis 129:709-714. Http://dx.doi.org/10.1093/infdis/129.6.709.
18. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. 2005. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol 79:2900-2909. Http://dx.doi.org/10.1128/JVI.79.5.2900 -2909.2005.
19. LoBue AD, Lindesmith L, Yount B, Harrington PR, Thompson JM, Johnston RE, Moe CL, Baric RS. 2006. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24:5220-5234. Http://dx.doi.org/10.1016/j.vaccine.2006.03.080.
20. Noel JS, Ando T, Leite JP, Green KY, Dingle KE, Estes MK, Seto Y, Monroe SS, Glass RI. 1997. Correlation of patient immune responses with genetically characterized small round-structured viruses involved in outbreaks of nonbacterial acute gastroenteritis in the United States, 1990 to 1995. J Med Virol 53:372-383. Http://dx.doi.org/10.1002/(SICI)1096-9 071(199712)53:4-372::AID-JMV10-3.0.CO;2-H.
21. Iritani N, Seto T, Hattori H, Natori K, Takeda N, Kubo H, Yamano T, Ayata M, Ogura H, Seto Y. 2007. Humoral immune responses against norovirus infections of children. J Med Virol 79:1187-1193. Http://dx.doi.org/10.1002/jmv.20897.
22. Jiang X, Matson DO, Ruiz-Palacios GM, Hu J, Treanor J, Pickering LK. 1995. Expression, self-assembly, and antigenicity of a snow mountain agent-like calicivirus capsid protein. J Clin Microbiol 33:1452-1455.
23. Treanor JJ, Jiang X, Madore HP, Estes MK. 1993. Subclass-specific serum antibody responses to recombinant Norwalk virus capsid antigen (rNV) in adults infected with Norwalk, Snow Mountain, or Hawaii virus. J Clin Microbiol 31:1630-1634.
24. Rockx B, Baric RS, de Grijs I, Duizer E, Koopmans MPG. 2005. Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J Med Virol 77:439-446. Http://dx.doi.org/10.1002/jmv.20473.
25. Madore HP, Treanor JJ, Buja R, Dolin R. 1990. Antigenic relatedness among the Norwalk-like agents by serum antibody rises. J Med Virol 32: 96-101. Http://dx.doi.org/10.1002/jmv.1890320206.
26. Higo-Moriguchi K, Shirato H, Someya Y, Kurosawa Y, Takeda N, Taniguchi K. 2014. Isolation of cross-reactive human monoclonal antibodies that prevent binding of human noroviruses to histo-blood group antigens. J Med Virol 86:558-567. Http://dx.doi.org/10.1002/jmv.23734.
27. Farkas T, Thornton SA, Wilton N, Zhong W, Altaye M, Jiang X. 2003. Homologous versus heterologous immune responses to Norwalk-like viruses among crew members after acute gastroenteritis outbreaks on 2 US Navy vessels. J Infect Dis 187:187-193. Http://dx.doi.org/10.1086/367809.
28. Green KY, Lew JF, Jiang X, Kapikian AZ, Estes MK. 1993. Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J Clin Microbiol 31:2185-2191.
29. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM. 2011. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 365:2178-2187. Http://dx.doi.org/10.1056/NEJMoa1101245.
30. Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, Atmar RL. 2010. Serological correlate of protection against norovirusinduced gastroenteritis. J Infect Dis 202:1212-1218. Http://dx.doi.org/10.1086/656364.
31. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. 2002. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol 76:12335-12343. Http://dx.doi.org/10.1128 /JVI.76.23.12335-12343.2002.
32. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, Ramani S, Hill H, Ferreira J, Graham DY. 2014. Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis 209:1016-1022. Http://dx.doi.org/10.1093/infdis/jit620.
33. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, Graham DY. 2008. Norwalk virus shedding after experimental human infection. Emerg Infect Dis 14:1553-1557. Http://dx.doi.org/10.3201 /eid1410.080117.
34. Jiang X, Wang M, Graham DY, Estes MK. 1992. Expression, selfassembly, and antigenicity of the Norwalk virus capsid protein. J Virol 66:6527-6532.
35. Vega E, Barclay L, Gregoricus N, Shirley SH, Lee D, Vinjé J. 2013. Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009-2013. J Clin Microbiol 52:147-155. Http://dx.doi.org/10.1128 /JCM.02680-13.
36. Zheng D-P, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. 2006. Norovirus classification and proposed strain nomenclature. Virology 346:312-323. Http://dx.doi.org/10.1016/j.virol.2005.11.015.
37. Czakó R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK. 2012. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol 19:284-287. Http://dx.doi.org/10.1128/CVI.05592-11.
38. Hall AJ, Lopman BA, Payne DC, Patel MM, Gastañaduy PA, Vinjé J, Parashar UD. 2013. Norovirus disease in the United States. Emerg Infect Dis 19:1198-1205. Http://dx.doi.org/10.3201/eid1908.130465.
39. Choi J-M, Hutson AM, Estes MK, Prasad BVV. 2008. Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci USA 105:9175-9180. Http://dx.doi.org/10.1073/pnas.0803275105.
40. Cao S, Lou Z, Tan M, Chen Y, Liu Y, Zhang Z, Zhang XC, Jiang X, Li X, Rao Z. 2007. Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol 81:5949-5957. Http://dx.doi.org/10.1128 /JVI.00219-07.
41. Tamminen K, Huhti L, Vesikari T, Blazevic V. 2013. Pre-existing immunity to norovirus GII-4 virus-like particles does not impair de novo immune responses to norovirus GII-12 genotype. Viral Immunol 26:167-170. Http://dx.doi.org/10.1089/vim.2012.0082.
42. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS. 2009. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol 83:3212-3227. Http://dx.doi.org/10.1128/JVI.01650-08.
43. Parra GI, Bok K, Taylor R, Haynes JR, Sosnovtsev SV, Richardson C, Green KY. 2012. Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 30:3580-3586. Http://dx.doi.org/10.1016/j.vaccine.2012.03.050.
44. Debbink K, Lindesmith LC, Donaldson EF, Swanstom J, Baric RS. 2014. Chimeric GII.4 norovirus virus-like particle based vaccines induce broadly blocking immune responses. J Virol 88:7256-7266. Http://dx.doi.org/10.1128/JVI.00785-14.
45. Cubitt WD, Green KY, Payment P. 1998. Prevalence of antibodies to the Hawaii strain of human calicivirus as measured by a recombinant protein based immunoassay. J Med Virol 54:135-139. Http://dx.doi.org/10.1002 /(SICI)1096-9071(199802)54:2<135::AID-JMV11>3.0.CO;2-I.
46. Hale A, Mattick K, Lewis D, Estes M, Jiang X, Green J, Eglin R, Brown D. 2000. Distinct epidemiological patterns of Norwalk-like virus infection. J Med Virol 62:99 -103. Http://dx.doi.org/10.1002 /1096-9071(200009)62:1-99::AID-JMV15-3.0.CO;2-0.
47. Noel JS, Fankhauser RL, Ando T, Monroe SS, Glass RI. 1999. Identification of a distinct common strain of "Norwalk-like viruses" having a global distribution. J Infect Dis 179:1334-1344. Http://dx.doi.org/10.1086 /314783.
48. Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng D-P, Vinje J, Baric RS. 2008. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 5:e31. Http://dx.doi.org/10.1371/journal.pmed.0050031.
49. Siebenga JJ, Lemey P, Kosakovsky Pond SL, Rambaut A, Vennema H, Koopmans M. 2010. Phylodynamic reconstruction reveals norovirus GII.4 epidemic expansions and their molecular determinants. PLoS Pathog 6:e1000884. .